Mainz Biomed B.V. (MYNZ) 是一家上市公司 属于 医疗保健 板块，经营于 Medical - Diagnostics & Research 行业. 公司总部位于 Mainz, 德国. 现任CEO为 Guido Baechler.
MYNZ 拥有 IPO日期为 2021-11-05, 19 名全职员工, 在 NASDAQ Capital Marke, 市值为 $2.86M.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
